About Alpha-1A adrenergic receptor
Alpha-1A adrenergic receptor (ADRA1A) is a protein
from Homo sapiens identified by UniProt accession
P35348, 466 residues long.
MolForge cross-references it against 0 known binders and
315 disease associations.
Target properties
| Protein name | Alpha-1A adrenergic receptor |
| UniProt accession | P35348 |
| Gene | ADRA1A |
| Organism | Homo sapiens |
| Length | 466 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (315)
Diseases linked to this target (Open Targets).
- hypertension · score 0.63
- benign prostatic hyperplasia · score 0.61
- myocardial infarction · score 0.61
- Nasal congestion · score 0.61
- common cold · score 0.61
- seasonal allergic rhinitis · score 0.61
- hypotension · score 0.60
- pain · score 0.60
- sinusitis · score 0.60
- hemorrhoid · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P35348-F1 | alphafold | PREDICTED | 70.28 | — |
Amino-acid sequence (466 residues)
MVFLSGNASD SSNCTQPPAP VNISKAILLG VILGGLILFG VLGNILVILS VACHRHLHSV THYYIVNLAV ADLLLTSTVL PFSAIFEVLG YWAFGRVFCN IWAAVDVLCC TASIMGLCII SIDRYIGVSY PLRYPTIVTQ RRGLMALLCV WALSLVISIG PLFGWRQPAP EDETICQINE EPGYVLFSAL GSFYLPLAII LVMYCRVYVV AKRESRGLKS GLKTDKSDSE QVTLRIHRKN APAGGSGMAS AKTKTHFSVR LLKFSREKKA AKTLGIVVGC FVLCWLPFFL VMPIGSFFPD FKPSETVFKI VFWLGYLNSC INPIIYPCSS QEFKKAFQNV LRIQCLCRKQ SSKHALGYTL HPPSQAVEGQ HKDMVRIPVG SRETFYRISK TDGVCEWKFF SSMPRGSARI TVSKDQSSCT TARVRSKSFL QVCCCVGPST PSLDKNHQVP TIKVHTISLS ENGEEV
Explore Alpha-1A adrenergic receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets